Exact Mass: 654.2312
Exact Mass Matches: 654.2312
Found 207 metabolites which its exact mass value is equals to given mass value 654.2312,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Mezerein
Crystals or white powder. (NTP, 1992) Mezerein is a diterpenoid. D009676 - Noxae > D002273 - Carcinogens D000970 - Antineoplastic Agents
Coproporphyrin I
Coproporphyrin I is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrin I is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Coproporhyrin I is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life.
Coproporphyrin III
Coproporphyrin III is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. Coproporphyrin III is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia, which are inherited disorders. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Excreted in small amounts in urine and faeces, found in blood, yeast, microorganisms etc. By-product of Haem formation in vivo, due to oxidation of the porphyrinogen (CCD) Coproporphyrin III (Zincphyrin) is a naturally occurring porphyrin derivative that is mainly found in urine[1][2].
cryptophycin
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent
Citbismine F
Citbismine F is found in citrus. Citbismine F is an alkaloid from Citrus paradisi (Marsh grapefruit Alkaloid from Citrus paradisi (Marsh grapefruit). Citbismine F is found in citrus.
Coproporphyrin II
Coproporphyrin II is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 1\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically. Coproporphyrin II is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Coproporhyrin II is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 1\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically.
Coproporphyrin IV
Coproporphyrin IV is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 2\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically. Coproporphyrin IV is a tetrapyrrole dead-end product from the spontaneous oxidation of the methylene bridges of coproporphynogen, arising from heme synthesis and secreted in feces and urine. Increased levels of coproporphyrins can indicate congenital erythropoietic porphyria or sideroblastic anaemia. Porphyria is a pathological state characterised by abnormalities of porphyrin metabolism and results in the excretion of large quantities of porphyrins in the urine and in extreme sensitivity to light. A large number of factors are capable of increasing porphyrin excretion, owing to different and multiple causes and etiologies: 1) the main site of the chronic hepatic porphyria disease process concentrates on the liver, 2) a functional and morphologic liver injury is almost regularly associated with this chronic porphyria, 3) the toxic form due to occupational and environmental exposure takes mainly a subclinical course. Hepatic factors includes disturbance in coproporphyrinogen metabolism, which results from inhibition of coproporphyrinogen oxidase as well as from the rapid loss from, and diminished utilization of coproporphyrinogen in the hepatocytes, which may also explain why coproporphyrin, its autoxidation product, predominates physiologically in the urine; decreased biliary excretion of coproporphyrin leading to a compensatory urinary excretion, so that the coproporphyrin ring isomer ratio (1:III) becomes a sensitive index for impaired liver function and intrahepatic cholestasis; and disturbed activity of hepatic uroporphyrinogen decarboxylase. In itself, secondary coproporphyrinuria is not associated with porphyria symptoms of a hepatologic-gastroenterologic, neurologic, or dermatologic order, even though coproporphyrinuria can occur with such symptoms. (PMID: 3327428). Coproporhyrin IV is a porphyrin metabolite arising from heme synthesis. Porphyrins are pigments found in both animal and plant life. This is a rare coproporphyrin isomer and it constitues only 2\\% of all coproporphyrins. This isomer appears to arise spontaneously as opposed to enzymatically.
Isocoproporphyrin
Isocoproporphyrin is a porphyrin derivative found in the feces and in urine for patients suffering from PCT (porphyria cutanea tarda). PCT is probably the most common of the porphyrias. It manifests as vesicle formation in sun-exposed areas, particularly the dorsum of the hands, A finding that is virtually diagnostic of PCT is the presence of isocoproporphyrin in stool. A porphyrin derivative found in the feces and in urine for patients suffering from PCT (porphyria cutanea tarda). PCT is probably the most common of the porphyrias. It manifests as vesicle formation in sun-exposed areas, particularly the dorsum of the hands, A finding that is virtually diagnostic of PCT is the presence of isocoproporphyrin in stool [HMDB]
cryptophycin
silvestrol
Thiomarinol D
An organosulfur heterocyclic compound produced by a marine bacterium Alteromonas rava and has been shown to exhibit antibacterial activity against Gram-positive and Gram-negative bacteria. D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams
(2R,3R,4S)-(-)-3alpha-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylisolariciresinol
(S)-4-(4-hydroxyphenyl)-2-butanol 2-O-[6-O-(3,5-dimethoxy-4-O-alpha-L-rhamnopyranosylgalloyl)-beta-D-glucopyranoside]
6-O-(3-O-p-coumaroyl-alpha-L-rhamnopyranosyl)catalpol|6-O-(3-O-trans-p-coumaroyl)-alpha-L-rhamnopyranosylcatalpol
3??,5??,8??,15??-Tetraacetoxy-7??-benzoyloxyjatropha-6(17),11E-dien-9,14-dione
6-O-alpha-L-(4-O-trans-p-coumaroyl)rhamnopyranosylcatalpol
(7S,8R)-dihydrodehydrodiconiferyl alcohol 9-O-beta-D-apiofuranosyl-(1->6)-O-beta-D-glucopyranoside
6-O-(6-O-trans-p-hydroxycinnamoyl)-beta-D-glucopyranosylaucubin|salviifolioside II
13-deacetoxy-13,15-epoxy-11(15-->1)abeo-13-epi-baccatin VI|13-Deacetoxy-13,15-epoxy-11(15鈥樏傗垎1)-abeo-13-epi-baccatin VI
(7R,8S)-dihydrodehydrodiconiferyl alcohol-4-O-alpha-L-rhamnopyranosyl-3-O-beta-D-glucopyranoside
(2S,2S)-2,2-(((1S,2S,3S,4S)-2,4-bis(4-hydroxyphenyl)cyclobutanedicarbonyl)bis(azanediyl))bis(3-(4-hydroxyphenyl)propanoic acid)|abrusamide B
5S-1,7-bis(3,4-dihydroxyphenyl)-5-O-beta-D-(2-O-feruloylxylopyranosyl)heptan-3-one|oregonoyl B
3,4-dihydroxyphenethoxy-8-O-beta-D-[6-O-(4-O-beta-D-glucopyranosyl)-feruloyl]-glucopyranoside
cinnacassoside B|dihydrodehydrodiconiferyl alcohol 9-beta-D-apiofuranosyl-(1?6)-beta-D-glucopyranoside
15-O-acetylcheiradone|rel-(2aR,5S,5aS,6S,6aS,7R,8R,9aS,10aR,10bS)-5,7,9a-tris(acetyloxy)-5a-[(acetyloxy)methyl]-6-benzoyloxy-2,2a,5,5a,6,6a,7,8,9,9a,10a,10b-dodecahydro-2,2,8,10a-tetramethyl-10H-azuleno[5,6,7-cd]isobenzofuran-10-one
5,7,2-tri-O-methylflavanone-4-O-beta-D-galactopyranosyl-(1 -> 3)-beta-D-glucopyranoside
2-(3,4-dihydroxyphenyl)-2-methoxyethyl 4-O-[(E)-caffeoyl]-3-O-(alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside|campneoside I|campneosides I
(2S,3S,3aR,4R,4aR,5R,8S,8aR,9S,10aR)-3,5,10a-triacetoxy-4a-(acetoxymethyl)-9-hydroxy-2,9-dimethyl-8-(methylethenyl)-10-oxo-1,2,3,3a,4,4a,5,8,8a,9,10,10a-dodecahydrobenzo[f]-azulen-4-yl benzoate|3,7,15,17-O-tetraacetyl-5-O-benzoyl-13-hydroxymyrsinol|isodecipinone
(2S,3S,3aR,4R,4aR,5R,8S,8aR,9S,10aR)-3,5,9-triacetoxy-4a-(acetoxymethyl)-10a-hydroxy-2,9-dimethyl-8-(methylethenyl)-10-oxo-1,2,3,3a,4,4a,5,8,8a,9,10,10a-dodecahydrobenzo[f]-azulen-4-yl benzoate|decipinone
1beta-furanoyl-2beta,3alpha,7alpha,8beta,11-pentaacetoxy-4alpha,5alpha-dihydroxydihydroagarofuran|1??-Furanoyl-2??,3??,7??,8??,11-pentaacetoxy-4??,5??-dihydroxy-dihydroagarofuran
Silvestrol
Silvestrol is an organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity. It has a role as a metabolite and an antineoplastic agent. It is an organic heterotricyclic compound, a member of dioxanes, an ether and a methyl ester. Silvestrol is a natural product found in Aglaia foveolata and Aglaia silvestris with data available. An organic heterotricyclic compound that consists of a 2,3,3a,8b-tetrahydro-H-benzo[b]cyclopenta[d]furan framework substituted by hydroxy groups at positions C-1 and C-8b, a methoxycarbonyl group at C-2, a phenyl group at C-3, a 4-methoxyphenyl group at C-3a, a methoxy group at C-8 and a 1,4-dioxan-2-yloxy group at position C-6 which in turn is substituted by a methoxy group at position 3 and a 1,2-dihydroxyethyl group at position 6. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.
Coproporphyrin III
Coproporphyrin III (Zincphyrin) is a naturally occurring porphyrin derivative that is mainly found in urine[1][2].
C30H38O16_(1aS,1bS,2S,5aR,6S,6aS)-6-({6-Deoxy-2-O-[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]-alpha-L-mannopyranosyl}oxy)-1a-(hydroxymethyl)-1a,1b,2,5a,6,6a-hexahydrooxireno[4,5]cyclopenta[1,2-c]pyran-2-yl beta-D-glucopyranoside
C30H38O16_(1aS,1bS,2S,5aR,6S,6aS)-6-({6-Deoxy-4-O-[(2E)-3-(4-hydroxyphenyl)-2-propenoyl]-alpha-L-mannopyranosyl}oxy)-1a-(hydroxymethyl)-1a,1b,2,5a,6,6a-hexahydrooxireno[4,5]cyclopenta[1,2-c]pyran-2-yl beta-D-glucopyranoside
[(2S,3R,4R,5R,6S)-2-[[(1aS,1bS,2S,5aR,6S,6aS)-1a-(hydroxymethyl)-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bH-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl]oxy]-4,5-dihydroxy-6-methyloxan-3-yl] (E)-3-(4-hydroxyphenyl)prop-2-enoate
9,9-di-O-E-p-Coumaroyl-(8R,8R)-secoisolariciresinol
9-O-E-p-Coumaroyl-9-O-Z-p-coumaroyl-(8R,8R)-secoisolariciresinol
9,9-di-O-Z-p-Coumaroyl-(8R,8R)-secoisolariciresinol
[(2S,3R,4R,5R,6S)-2-[[(1aS,1bS,2S,5aR,6S,6aS)-1a-(hydroxymethyl)-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,5a,6,6a-tetrahydro-1bH-oxireno[5,6]cyclopenta[1,3-c]pyran-6-yl]oxy]-4,5-dihydroxy-6-methyloxan-3-yl] (E)-3-(4-hydroxyphenyl)prop-2-enoate_major
Phe Tyr Tyr Tyr
Thr Trp Trp Tyr
Thr Trp Tyr Trp
Thr Tyr Trp Trp
Trp Thr Trp Tyr
Trp Thr Tyr Trp
Trp Trp Thr Tyr
Trp Trp Tyr Thr
Trp Tyr Thr Trp
Trp Tyr Trp Thr
Tyr Phe Tyr Tyr
Tyr Thr Trp Trp
Tyr Trp Thr Trp
Tyr Trp Trp Thr
Tyr Tyr Phe Tyr
Tyr Tyr Tyr Phe
Citbismine F
(3S)-6,6-DIMETHYL-5-OXOTHIOMORPHOLINE-3-CARBOXYLICACID
2-[2-[2-chloro-3-[2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole,4-methylbenzenesulfonate
(1S)-[1,1-binaphthalene]-2,2-diylbis[1,1-diphenyl-1,1-Phosphine oxide
1-[(3R)-3-(3,4-dichlorophenyl)-3-[2-(4-phenyl-1-azoniabicyclo[2.2.2]octan-1-yl)ethyl]piperidin-1-yl]-2-(3-propan-2-yloxyphenyl)ethanone chloride
Ccris 4674
D009676 - Noxae > D002273 - Carcinogens D000970 - Antineoplastic Agents
(13E)-10-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(2-methylpropyl)-16-[1-(3-phenyloxiran-2-yl)ethyl]-1,4-dioxa-8,11-diazacyclohexadec-13-ene-2,5,9,12-tetrone
D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents D000890 - Anti-Infective Agents > D000935 - Antifungal Agents
3-[8,13,18-Tris(2-carboxyethyl)-3,7,12,17-tetramethyl-21,23-dihydroporphyrin-2-yl]propanoic acid
3-(Carboxymethyl)-12-ethyl-8,13,17-trimethyl-21h,23h-porphine-2,7,18-tripropanoic acid
3,8,12,17-Tetramethyl-2,7,13,18-porphinetetrapropionate
3-[8,12,18-Tris(2-carboxyethyl)-3,7,13,17-tetramethyl-21,23-dihydroporphyrin-2-yl]propanoic acid
(1aS)-2alpha-(beta-D-Glucopyranosyloxy)-6alpha-[4-O-(p-hydroxycinnamoyl)-alpha-L-rhamnopyranosyloxy]-1a,1balpha,2,5aalpha,6,6abeta-hexahydrooxireno[4,5]cyclopenta[1,2-c]pyran-1abeta-methanol
(Z)-12,13-Bis[(trimethylsilyl)oxy]-9-octadecenoic acid 2-(4-bromophenyl)-2-oxoethyl ester
(Z)-9,10-Bis[(trimethylsilyl)oxy]-12-octadecenoic acid 2-(4-bromophenyl)-2-oxoethyl ester
epi-silvestrol
An organic heterotricyclic compound that is a 5-epimer of silvestrol. Isolated from Aglaia silvestris, it exhibits antineoplastic activity.
3-[9,14,19-tris(2-carboxyethyl)-5,10,15,20-tetramethyl-21,22,23,24-tetraazapentacyclo[16.2.1.1³,⁶.1⁸,¹¹.1¹³,¹⁶]tetracosa-1,3(24),4,6,8,10,12,14,16,18(21),19-undecaen-4-yl]propanoic acid
(2s,3r,4s,5r,6s)-4,5-dihydroxy-6-{[(1s,2s,4s,5s,6r,10s)-2-(hydroxymethyl)-10-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3,9-dioxatricyclo[4.4.0.0²,⁴]dec-7-en-5-yl]oxy}-2-methyloxan-3-yl (2z)-3-(4-hydroxyphenyl)prop-2-enoate
(3s)-3,9-dihydroxy-6-methoxy-3-(2-oxopropyl)-8-{[3,4,5-trihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-2,4-dihydroanthracen-1-one
2-{[8-(4-hydroxy-3-methoxyphenyl)-6-(hydroxymethyl)-3-methoxy-7-{[(3,4,5-trihydroxyoxan-2-yl)oxy]methyl}-5,6,7,8-tetrahydronaphthalen-2-yl]oxy}-6-(hydroxymethyl)oxane-3,4,5-triol
(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-hydroxyethoxy]-5-hydroxy-2-(hydroxymethyl)-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
(1s,3as,4r,6ar)-1-[(2r,3r)-2-(2h-1,3-benzodioxol-5-yl)-7-methoxy-3-(methoxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-4-[(4,6-dimethoxy-2h-1,3-benzodioxol-5-yl)oxy]-tetrahydro-1h-furo[3,4-c]furan-3a-ol
1-[2-(2h-1,3-benzodioxol-5-yl)-7-methoxy-3-(methoxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]-4-[(4,6-dimethoxy-2h-1,3-benzodioxol-5-yl)oxy]-tetrahydro-1h-furo[3,4-c]furan-3a-ol
(2r,3s,4s,5r,6r)-5-{[(2s,3r,4r)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy}-6-{[(1r,2s,3s)-7-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-6-methoxy-1,2,3,4-tetrahydronaphthalen-2-yl]methoxy}-2-(hydroxymethyl)oxane-3,4-diol
8-{[(2e,4r)-4-[(2s,3r,4r,5s)-3,4-dihydroxy-5-[(2e,4r,5s)-5-hydroxy-4-methylhept-2-en-1-yl]oxan-2-yl]-4-hydroxy-3-methylbut-2-enoyl]oxy}-n-{5-hydroxy-[1,2]dithiolo[4,3-b]pyrrol-6-yl}octanimidic acid
(2r,3r,4r,5r,6r)-6-[2-(3,4-dihydroxyphenyl)-2-methoxyethoxy]-5-hydroxy-2-(hydroxymethyl)-4-{[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2e)-3-(3,4-dihydroxyphenyl)prop-2-enoate
(2r)-3-hydroxy-3-methyl-1-({7-oxofuro[3,2-g]chromen-9-yl}oxy)butan-2-yl (1s,3r,4r,5r)-1,3,4-trihydroxy-5-{[(2e)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoyl]oxy}cyclohexane-1-carboxylate
{6-[2-(3,4-dihydroxyphenyl)ethoxy]-3,5-dihydroxy-4-{[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}oxan-2-yl}methyl 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
(3s,6r,10s,13e,16s)-10-[(3-chloro-4-methoxyphenyl)methyl]-9,12-dihydroxy-6-methyl-3-(2-methylpropyl)-16-[(1s)-1-[(2r,3r)-3-phenyloxiran-2-yl]ethyl]-1,4-dioxa-8,11-diazacyclohexadeca-8,11,13-triene-2,5-dione
13-deacetoxy-13,15-epoxy-11(15-1)-abeo-13-epi-baccatinvi
{"Ingredient_id": "HBIN001159","Ingredient_name": "13-deacetoxy-13,15-epoxy-11(15-1)-abeo-13-epi-baccatinvi","Alias": "NA","Ingredient_formula": "C35H42O12","Ingredient_Smile": "CC1=C2C(C(C3(C(CC4C(C3C(C25CC1OC5(C)C)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC(=O)C)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "26040","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
13-deacetoxy-13,15-epoxy-11(15→1)-abeo-13-epi-baccatin vi
{"Ingredient_id": "HBIN001160","Ingredient_name": "13-deacetoxy-13,15-epoxy-11(15\u21921)-abeo-13-epi-baccatin vi","Alias": "NA","Ingredient_formula": "C35H42O12","Ingredient_Smile": "CC1=C2C(C(C3(C(CC4C(C3C(C25CC1OC5(C)C)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)OC(=O)C)C)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "4705","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
1β-furanoyl-2β,3α,7α,8β,11-pentaacetoxy-4α,5α-dihydroxy-dihydroagarofuran
{"Ingredient_id": "HBIN002395","Ingredient_name": "1\u03b2-furanoyl-2\u03b2,3\u03b1,7\u03b1,8\u03b2,11-pentaacetoxy-4\u03b1,5\u03b1-dihydroxy-dihydroagarofuran","Alias": "NA","Ingredient_formula": "C30H38O16","Ingredient_Smile": "CC(=O)OCC12C(C(C3C(C1(C(C(C(C2OC(=O)C4=COC=C4)OC(=O)C)OC(=O)C)(C)O)OC3(C)C)O)OC(=O)C)OC(=O)C","Ingredient_weight": "NA","OB_score": "NA","CAS_id": "NA","SymMap_id": "SMIT15425","TCMID_id": "8022","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "NA","DrugBank_id": "NA"}
